Press Releases

Year

Aug 09, 2018

Wave Life Sciences Reports Second Quarter 2018 Financial Results and Provides Business Update

CAMBRIDGE, Mass. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced financial results for the second quarter ended June 30, 2018

Jul 02, 2018

Wave Life Sciences Receives Positive Opinion for Orphan Drug Designation in the European Union for WVE-210201

Investigational WVE-210201 in development for treatment of Duchenne muscular dystrophy patients amenable to exon 51 skipping Patients currently enrolling in global Phase 1 clinical trial CAMBRIDGE, Mass. , July 02, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.

Jun 25, 2018

Wave Life Sciences to Present at Parent Project Muscular Dystrophy Annual Conference

CAMBRIDGE, Mass. , June 25, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Paul Bolno , MD, MBA, President and Chief Executive

May 31, 2018

Wave Life Sciences to Present at the Jefferies 2018 Healthcare Conference

CAMBRIDGE, Mass. , May 31, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Paul Bolno , M.D., MBA, President and Chief Executive

May 09, 2018

Wave Life Sciences Reports First Quarter 2018 Financial Results and Provides Business Update

CAMBRIDGE, Mass. , May 09, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced financial results for the first quarter ended March 31, 2018 ,

May 07, 2018

Wave Life Sciences Highlights Progress on Hepatic Collaboration with Pfizer

With the designation of five targets, Pfizer nominates the maximum permitted under collaboration Collaboration moving toward candidate selection CAMBRIDGE, Mass. , May 07, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational

Apr 17, 2018

Wave Life Sciences to Present Data on ALS and FTD Programs and on Huntington's Disease at the 2018 American Academy of Neurology Annual Meeting

CAMBRIDGE, Mass. , April 17, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, will present key data on its amyotrophic lateral sclerosis (ALS) and

Apr 10, 2018

Wave Life Sciences and Deep Genomics Form Collaboration to Discover Novel Therapies for Genetic Neuromuscular Disorders

CAMBRIDGE, Mass. and TORONTO, April 10, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, and Deep Genomics Inc.

Apr 05, 2018

Wave Life Sciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass. , April 05, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Paul Bolno , MD, MBA, President and Chief Executive

Mar 12, 2018

Wave Life Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Business Update

Initiated three clinical trials in 2017 and on track to deliver three additional development programs in 2018 Neurology pipeline growing; candidate in spinocerebellar ataxia type 3 to be named by year end 2018 CAMBRIDGE, Mass. , March 12, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.